Sangamo Therapeutics Inc
NASDAQ:SGMO
Income Statement
Earnings Waterfall
Sangamo Therapeutics Inc
Revenue
|
176.2m
USD
|
Operating Expenses
|
-278.8m
USD
|
Operating Income
|
-102.6m
USD
|
Other Expenses
|
-155.2m
USD
|
Net Income
|
-257.8m
USD
|
Income Statement
Sangamo Therapeutics Inc
Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||||||||||
Revenue |
24
N/A
|
28
+15%
|
31
+13%
|
38
+22%
|
46
+21%
|
51
+12%
|
49
-4%
|
46
-8%
|
40
-13%
|
30
-24%
|
25
-16%
|
20
-23%
|
19
-1%
|
19
-3%
|
23
+24%
|
32
+38%
|
37
+13%
|
46
+25%
|
59
+29%
|
71
+20%
|
85
+20%
|
80
-5%
|
76
-5%
|
74
-2%
|
102
+38%
|
108
+5%
|
112
+4%
|
147
+32%
|
118
-20%
|
132
+11%
|
138
+5%
|
109
-21%
|
111
+2%
|
113
+2%
|
114
+1%
|
112
-2%
|
111
-1%
|
241
+117%
|
219
-9%
|
201
-8%
|
176
-12%
|
|
Operating Income | ||||||||||||||||||||||||||||||||||||||||||
Operating Expenses |
(51)
|
(55)
|
(60)
|
(68)
|
(73)
|
(77)
|
(80)
|
(81)
|
(86)
|
(87)
|
(97)
|
(98)
|
(92)
|
(92)
|
(82)
|
(85)
|
(93)
|
(106)
|
(126)
|
(141)
|
(160)
|
(180)
|
(191)
|
(202)
|
(208)
|
(213)
|
(222)
|
(232)
|
(248)
|
(263)
|
(280)
|
(295)
|
(294)
|
(295)
|
(294)
|
(298)
|
(313)
|
(320)
|
(319)
|
(309)
|
(279)
|
|
Selling, General & Administrative |
(14)
|
(14)
|
(15)
|
(15)
|
(16)
|
(17)
|
(18)
|
(19)
|
(19)
|
(20)
|
(26)
|
(26)
|
(26)
|
(28)
|
(23)
|
(25)
|
(27)
|
(30)
|
(35)
|
(40)
|
(45)
|
(52)
|
(55)
|
(59)
|
(62)
|
(61)
|
(64)
|
(65)
|
(67)
|
(67)
|
(66)
|
(64)
|
(63)
|
(62)
|
(61)
|
(62)
|
(63)
|
(66)
|
(66)
|
(63)
|
(57)
|
|
Research & Development |
(37)
|
(41)
|
(45)
|
(53)
|
(57)
|
(60)
|
(62)
|
(62)
|
(67)
|
(68)
|
(71)
|
(72)
|
(66)
|
(63)
|
(59)
|
(60)
|
(66)
|
(76)
|
(91)
|
(101)
|
(115)
|
(126)
|
(134)
|
(141)
|
(146)
|
(153)
|
(158)
|
(167)
|
(181)
|
(196)
|
(214)
|
(231)
|
(231)
|
(233)
|
(233)
|
(236)
|
(250)
|
(255)
|
(253)
|
(245)
|
(222)
|
|
Other Operating Expenses |
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(27)
N/A
|
(28)
-3%
|
(29)
-5%
|
(31)
-5%
|
(27)
+12%
|
(25)
+5%
|
(31)
-21%
|
(36)
-16%
|
(47)
-31%
|
(57)
-22%
|
(72)
-25%
|
(78)
-9%
|
(73)
+7%
|
(73)
N/A
|
(59)
+19%
|
(52)
+11%
|
(56)
-8%
|
(61)
-7%
|
(67)
-10%
|
(70)
-5%
|
(75)
-7%
|
(100)
-33%
|
(114)
-14%
|
(127)
-11%
|
(105)
+17%
|
(106)
0%
|
(110)
-4%
|
(85)
+23%
|
(130)
-53%
|
(131)
-1%
|
(142)
-8%
|
(187)
-31%
|
(183)
+2%
|
(182)
+1%
|
(179)
+2%
|
(186)
-4%
|
(201)
-8%
|
(79)
+61%
|
(101)
-27%
|
(107)
-7%
|
(103)
+4%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
3
|
5
|
7
|
8
|
9
|
10
|
8
|
10
|
10
|
8
|
9
|
9
|
8
|
8
|
6
|
5
|
6
|
7
|
8
|
9
|
11
|
12
|
13
|
11
|
|
Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(59)
|
(115)
|
(160)
|
(171)
|
|
Pre-Tax Income |
(27)
N/A
|
(27)
-3%
|
(29)
-5%
|
(30)
-5%
|
(26)
+13%
|
(25)
+6%
|
(30)
-20%
|
(35)
-17%
|
(46)
-32%
|
(57)
-22%
|
(71)
-26%
|
(78)
-9%
|
(72)
+8%
|
(72)
0%
|
(58)
+20%
|
(51)
+11%
|
(55)
-7%
|
(58)
-7%
|
(62)
-7%
|
(63)
-1%
|
(69)
-10%
|
(91)
-32%
|
(105)
-15%
|
(119)
-14%
|
(95)
+20%
|
(96)
-1%
|
(102)
-6%
|
(76)
+26%
|
(121)
-59%
|
(124)
-2%
|
(135)
-9%
|
(181)
-34%
|
(178)
+2%
|
(176)
+1%
|
(172)
+2%
|
(178)
-3%
|
(192)
-8%
|
(127)
+34%
|
(204)
-61%
|
(254)
-24%
|
(263)
-3%
|
|
Net Income | ||||||||||||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
4
|
6
|
5
|
5
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
6
|
5
|
5
|
|
Income from Continuing Operations |
(27)
|
(27)
|
(29)
|
(30)
|
(26)
|
(24)
|
(29)
|
(31)
|
(41)
|
(52)
|
(66)
|
(76)
|
(72)
|
(72)
|
(58)
|
(51)
|
(55)
|
(58)
|
(62)
|
(63)
|
(69)
|
(91)
|
(105)
|
(119)
|
(95)
|
(96)
|
(102)
|
(76)
|
(121)
|
(124)
|
(135)
|
(182)
|
(178)
|
(176)
|
(172)
|
(178)
|
(192)
|
(127)
|
(199)
|
(250)
|
(258)
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
(27)
N/A
|
(27)
-3%
|
(29)
-5%
|
(30)
-5%
|
(26)
+13%
|
(24)
+9%
|
(29)
-21%
|
(31)
-6%
|
(41)
-32%
|
(52)
-27%
|
(66)
-28%
|
(76)
-15%
|
(72)
+6%
|
(72)
0%
|
(58)
+20%
|
(51)
+11%
|
(55)
-7%
|
(58)
-7%
|
(62)
-7%
|
(63)
-1%
|
(68)
-9%
|
(90)
-32%
|
(104)
-15%
|
(119)
-14%
|
(95)
+20%
|
(96)
-1%
|
(102)
-6%
|
(76)
+25%
|
(121)
-60%
|
(124)
-2%
|
(135)
-9%
|
(181)
-34%
|
(178)
+2%
|
(176)
+1%
|
(172)
+2%
|
(178)
-3%
|
(192)
-8%
|
(127)
+34%
|
(199)
-56%
|
(250)
-26%
|
(258)
-3%
|
|
EPS (Diluted) |
-0.42
N/A
|
-0.43
-2%
|
-0.42
+2%
|
-0.46
-10%
|
-0.39
+15%
|
-0.35
+10%
|
-0.42
-20%
|
-0.44
-5%
|
-0.58
-32%
|
-0.73
-26%
|
-0.94
-29%
|
-1.08
-15%
|
-1.02
+6%
|
-1.02
N/A
|
-0.81
+21%
|
-0.6
+26%
|
-0.7
-17%
|
-0.67
+4%
|
-0.64
+4%
|
-0.61
+5%
|
-0.7
-15%
|
-0.89
-27%
|
-0.9
-1%
|
-1.02
-13%
|
-0.85
+17%
|
-0.83
+2%
|
-0.73
+12%
|
-0.53
+27%
|
-0.9
-70%
|
-0.88
+2%
|
-0.95
-8%
|
-1.24
-31%
|
-1.23
+1%
|
-1.22
+1%
|
-1.18
+3%
|
-1.12
+5%
|
-1.25
-12%
|
-0.75
+40%
|
-1.13
-51%
|
-1.4
-24%
|
-1.48
-6%
|